Albany Molecular Research (AMRI)
Albany Molecular Research Liabilities: 58.02M
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
- Accounts Payable
- Accounts Receivable
- Accruals Pro
- Altman Z-Score Pro
- Asset Utilization
- Beneish M-Score Pro
- Beta Pro
- Book Value
- Book Value per Share
- Capital Expenditures
- Cash Conversion Cycle Pro
- Cash Div. Payout Ratio TTM Pro
- Cash Financing
- Cash Financing TTM
- Cash Investing
- Cash Investing TTM
- Cash Operations
- Cash Operations TTM
- Cash and Equivalents
- Cash and ST Investments
- Current Ratio
- Days Inventory Outstanding Pro
- Days Payable Outstanding Pro
- Days Sales Outstanding Pro
- Debt to Equity Ratio
- Dividend
- Dividend Yield
- EBITDA Margin TTM Pro
- EBITDA TTM Pro
- EV / EBIT Pro
- EV / EBITDA Pro
- EV / Free Cash Flow Pro
- EV / Revenues Pro
- Earnings Per Share
- Earnings Per Share Growth
- Earnings Per Share TTM
- Earnings Yield
- Effective Tax Rate TTM Pro
- Enterprise Value
- Expenses
- Expenses TTM
- Free Cash Flow
- Free Cash Flow TTM
- Free Cash Flow Yield Pro
- Fundamental Score Pro
- Gross Profit Margin
- Gross Profit TTM
- Income from Cont. Ops Pro
- Interest Expense
- Interest Income
- Inventories
- KZ Index Pro
- Liabilities
- Long Term Debt
- Market Cap
- Net Income
- Net Income TTM
- Net PP&E
- Operating Earnings Yield Pro
- Operating Margin TTM Pro
- Operating PE Ratio Pro
- Other Comprehensive Income Pro
- PE 10 Pro
- PE Ratio
- PE Value Pro
- PEG Ratio
- PS Value Pro
- Payout Ratio TTM Pro
- Price
- Price / Book Value
- Price / Sales Ratio
- Price / Tangible Book Value Pro
- Profit Margin
- R&D Expense
- Receivables Turnover
- Retained Earnings
- Retained Earnings Growth
- Return on Assets
- Return on Equity
- Return on Invested Capital Pro
- Revenue Growth
- Revenue Per Share TTM
- Revenues
- Revenues TTM
- SG&A Expense
- Shareholders Equity
- Shares Outstanding
- Stock Buybacks
- Tangible Book Value Pro
- Tangible Book Value Per Share Pro
- Tangible Common Equity Ratio Pro
- Times Interest Earned TTM Pro
- Total Assets
- Total Return Price
- Valuation (Historical Mult.) Pro
- Valuation Percentage Pro
- Value Score Pro
Select a metric
Date range:
to
<Embed Chart>
Pro Save as Image
Pro Data Export
Copy the code below and paste
into the embed destination.
into the embed destination.
Attention
OK
AMRI Liabilities Rankings
| Overall | 76th percentile | 1031 of 4384 |
| Sector | 45th percentile | 273 of 504 in Healthcare |
| Industry | 33rd percentile | 105 of 159 in Biotechnology |
AMRI Liabilities Range, Past 5 Years
| Minimum | 51.34M | Mar 2008 |
| Maximum | 81.36M | Dec 2010 |
| Average | 63.24M |
About Total Liabilities
Liabilities are obligations of a company arising from past transactions or events which are expected to reduce assets when they are settled.
Total liabilities is a line item on the balance sheet.
Learn More
You may also be interested in these AMRI related companies
AMRI News
Listen to $AMRI Q1 2012 earnings call - live at 10:00 AM, ondemand after - http://stks.co/3k43
about 18 days ago by earningscast
about 18 days ago by earningscast
I need all the ones that horizon Alerted recently that im currently stuck in way down $RCON $AMRI $NFC $SINO and more to go up a lot
about 23 days ago by epime7heus
about 23 days ago by epime7heus
AMRI Launches SMARTSOURCING™ For Contract Manufacturing and Research Services
Apr 30, 8:00AM PR Newswire
Apr 30, 8:00AM PR Newswire
AMRI Announces Development and Manufacturing Deal with Biota Holdings Limited
Apr 17, 8:00AM PR Newswire
Apr 17, 8:00AM PR Newswire
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer
Apr 03, 8:01AM Benzinga
Apr 03, 8:01AM Benzinga
AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations
Mar 27, 8:00AM PR Newswire
Mar 27, 8:00AM PR Newswire
Albany Molecular Research (AMRI) Reports Q4 Loss of $0.19; Guides Contract Revs
Feb 07, 8:05AM Street Insider
Feb 07, 8:05AM Street Insider
AMRI CFO to Present at UBS 22nd Annual Global Healthcare Services Conference
Feb 01, 8:00AM PR Newswire
Feb 01, 8:00AM PR Newswire
Albany Molecular (AMRI) Announces Workforce Reduction, to Cease Facility Lease; Updates on Expected Charges
Dec 22, 5:08PM Street Insider
Dec 22, 5:08PM Street Insider
Insider Cluster-Buying At $AMRI. 23,900 shares purchased. http://stks.co/1Xse
about 165 days ago by abubnic
about 165 days ago by abubnic
Sterne Agee reiterated its “Buy” rating on $AMRI with a price target of $7.00.
about 165 days ago by abubnic
about 165 days ago by abubnic
$AMRI $5.00 Hagen Steven R officer (VP Pharmaceutical Dev & Mfg) S 198 @ $4.84 amnt $958 proc'd ($32) 5/6/2011
about 381 days ago by canarionyc
about 381 days ago by canarionyc
$AMRI http://chart.ly/xvpba4r Closed above 50 day on high volume, 10% of float is short, MACD looks ready
about 405 days ago by Tr8r_x
about 405 days ago by Tr8r_x
$AMRI discloses court ruling related to $RDY and 24-hour Allegra case. http://bit.ly/gkba7y
about 485 days ago by TradeHawk
about 485 days ago by TradeHawk
$AMRI Hagen Steven R officer (VP Pharmaceutical Dev & Mfg) sold 2,000 @ $5.20 totl $10,400.00 2010-12-06
about 524 days ago by canarionyc
about 524 days ago by canarionyc
start swing long 1k $AMRI on long time coming trend reversal, looking for 6.3 stop 5.3
about 709 days ago by Assailed
about 709 days ago by Assailed
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| AMRI | 2.71 | -0.05 | -1.81% | 83.39M |
| AMRC | 11.07 | -0.15 | -1.34% | 289.15M |
| AMPL | 0.185 | +0.01 | +2.83% | 10.38M |
| ALVR | 0.49 | +0.03 | +6.52% | 28.41M |
| ALV | 57.16 | -0.25 | -0.44% | 5.116B |
| ALU | 1.67 | +0.07 | +4.38% | 3.883B |
| ALTR | 34.42 | +0.66 | +1.96% | 11.11B |
| ALTI | 0.66 | +0.00 | +0.00% | 45.84M |
| ALTH | 1.80 | +0.00 | +0.00% | 192.53M |
| ALTE | 22.72 | -0.28 | -1.22% | 2.292B |
